MW Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows

By Steve Goldstein

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday.

The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage, instead of 2.4 milligrams. After 72 weeks, the higher dose version for people who weigh 113 kilograms (249 pounds) on average resulted in 20.7% weight loss after 72 weeks, compared to 17.4% with the lower dose version, and 2.4% with placebo.

The company said that a third of those with the higher dose achieved weight loss of at least 25% after 72 weeks, versus 16.7% on the lower dose and none on placebo.

The results of a trial of the higher-dose version on adults with type 2 diabetes and obesity are expected in a few months, Novo Nordisk said.

Novo Nordisk's stock (DK:NOVO.B) $(NVO)$ fell 2% in Copenhagen trade and are down 27% over the last three months.

Analysts at Argus Research said the stock is now trading at 22 times its estimated 2025 earnings, which is well below the five-year average of 31, after last year's disappointing trial study of the next-generation CagriSema drug. They rate the stock a buy with a $110 price target for the U.S.-listed shares.

-Steve Goldstein

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

January 17, 2025 08:23 ET (13:23 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.